Dr. Luis Ignacio Becerra-Cabal, MD

Dr. Becerra-Cabal practices at Neuroscience Consultants in Miami, Florida.

Dr. Becerra-Cabal's NPI, 1164493649, was assigned on January 31, 2006. Dr. Becerra-Cabal graduated from Pontifical Xavierian University in 1978. Dr. Becerra-Cabal holds Florida license ME109502.

Dr. Becerra-Cabal's primary practice is Neuroscience Consultants, at 21000 Ne 28th Ave, Miami, FL 33180 in Miami-Dade County. The practice phone is (786) 924-1311.

Dr. Becerra-Cabal's primary practice is Neuroscience Consultants in Miami, Florida. Dr. Becerra-Cabal is also affiliated with Jackson Memorial Hospital. The medical group on file is First Choice Neurology. Dmand AI also links Dr. Becerra-Cabal to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Becerra-Cabal practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Becerra-Cabal's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Becerra-Cabal is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Becerra-Cabal's licenses on file in 3 states: Florida, California and Pennsylvania.

Dmand AI lists acute mini-stroke (TIA), alzheimer's disease, carpal tunnel syndrome, cerebrovascular disease, epilepsy, essential tremor, fibromyalgia and chronic pain and head injury among the conditions Dr. Becerra-Cabal treats.

CMS data shows 13,750 Medicare services from Dr. Becerra-Cabal across 10 procedure codes in 2024, for 393 Medicare patients. Medicare paid $166,246 for them.

CMS counts 393 Medicare patients who saw Dr. Becerra-Cabal in 2024. The largest group is 75 to 84, with 144 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 42% are also on Medicaid. Their average risk score is 2.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Becerra-Cabal's median patient age at 68, with 60% women.

In 2024, Dr. Becerra-Cabal wrote 2,092 Medicare Part D claims for 349 patients. 82% of them were for generic drugs. CMS names the drug for 1,834 of them, across 45 drugs with 11 or more claims each, at $538,289 in total drug cost. In 2023, CMS named 2,361 claims across 49 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Becerra-Cabal for performance year 2024, reported individually. Dr. Becerra-Cabal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Becerra-Cabal as offering telehealth.

Dmand AI links 1 paper to Dr. Becerra-Cabal.

CMS Open Payments shows 1,153 general payments to Dr. Becerra-Cabal from 75 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Pfizer Inc. paid the most, $2,631.

Dr. Becerra-Cabal graduated from Pontifical Xavierian University in 1978.

Dr. Becerra-Cabal is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.